Oncobiomix files Form D for $2.5 million offering
The San Antonio biotech reported one investor and $100,000 raised toward a $2.5 million exempt securities offering, according to a Form D filed with the SEC.
Oncobiomix Inc., a Delaware corporation formed in 2023 and based in San Antonio, Texas, filed a Form D with the SEC as of September 16, 2026, disclosing a new exempt securities offering. The filing lists a date of first sale of September 14, 2026.1
The company is offering an option, warrant or other right to acquire another security1 under the Rule 506(b) exemption1. The total offering amount is set at $2,500,000, with $100,000 sold so far and $2,400,000 remaining to be sold.1 One investor has invested in the offering to date.1
The company selected "Decline to Disclose" for both its revenue range and net asset value range.1 The minimum investment accepted from any outside investor is listed as $0.1 The filing reports no sales commissions or finders' fees.1
The related person named in the filing is Michael Andre Liss, based at the same San Antonio address, listed as both an executive officer and director.1 The signature page identifies him as Michael A. Liss, M.D., Ph.D., serving as President, with a signature date of September 16, 2026.1
The offering is not being made in connection with a business combination transaction such as a merger, acquisition or exchange offer.1 The issuer indicated the offering is intended to last more than one year.1 The filing does not disclose additional details about the company's operations or the purpose of the proceeds beyond compensation to named executives.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.